A larger study in 288 CLL patient, 65% of whom had developed relapsed or refractory disease, found a 4% incidence of somatically-acquired MGA mutations, with a small but significant tendency among this group to have a worse overall response to treatment [334]. The gene discussed is MGA; the disease is B-cell chronic lymphocytic leukemia.